Curated News
By: NewsRamp Editorial Staff
September 22, 2026
Helus Pharma CEO to Speak at TD Cowen Neuropsychiatry Summit
TLDR
- Helus Pharma CEO presents at TD Cowen Summit, showcasing HLP003 in Phase 3 for depression with FDA Breakthrough Therapy Designation.
- Helus Pharma develops novel serotonergic agonists that activate serotonin pathways to promote neuroplasticity, with HLP003 in Phase 3 and HLP004 in Phase 2.
- Helus Pharma aims to help minds heal by developing treatments for depression, anxiety, and other mental health conditions, addressing a large unmet need.
- Helus Pharma, the commercial name of Cybin Inc., founded in 2019, is developing proprietary NSAs to improve mental health treatment.
Impact - Why it Matters
The TD Cowen Novel Mechanisms in Neuropsychiatry Summit provides a prominent platform for Helus Pharma to showcase its novel serotonergic agonists (NSAs) to key opinion leaders, investors, and industry peers. As mental health disorders like depression and anxiety continue to rise globally, innovative treatments that target serotonin pathways and promote neuroplasticity could offer new hope for patients who have not responded to existing therapies. Helus Pharma's lead candidate, HLP003, has already received Breakthrough Therapy Designation from the FDA, underscoring its potential to address a significant unmet need. With HLP003 in Phase 3 and HLP004 in Phase 2, the company is at a critical juncture where investor and partner interest can accelerate development and eventual commercialization. This fireside chat not only raises awareness of Helus Pharma's pipeline but also highlights the broader shift toward psychedelic-inspired and serotonergic medicines in psychiatry. For patients and investors alike, the event signals progress in a field that could revolutionize mental health care and create substantial market opportunities.
Summary
Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that CEO Michael Halstead will participate in a fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit. The virtual event is scheduled for September 23, 2026, at 9 a.m. EDT and will be webcast live. The discussion will likely center on the company's proprietary NSAs, which are synthetic molecules designed to activate serotonin pathways to promote neuroplasticity and address serious mental health conditions. Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and is committed to helping minds heal through innovative treatments for depression, anxiety, and other mental health disorders.
The company’s lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Another proprietary NSA, HLP004, is in Phase 2 for generalized anxiety disorder. With class-leading data, Helus Pharma aims to transform the treatment landscape by delivering durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com or follow the team on social media. Helus Pharma™ is a trademark of Cybin Corp. Investors can find the latest updates in the company’s newsroom at https://nnw.fm/HELP. The announcement was disseminated through NetworkNewsWire, a specialized communications platform and part of the Dynamic Brand Portfolio @ IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma CEO to Speak at TD Cowen Neuropsychiatry Summit
